Skip to main content

Coherus Oncology, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

CHRS$0.82+6.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

​​​​
​ · ​ · Page
​CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS​3
PART IFINANCIAL INFORMATION​5
ITEM 1Unaudited Condensed Consolidated Financial Statements​5
Condensed Consolidated Balance Sheets​5
​Condensed Consolidated Statements of Operations​6
​Condensed Consolidated Statements of Comprehensive Income (Loss)​7
​Condensed Consolidated Statements of Stockholders’ Equity (Deficit)​8
​Condensed Consolidated Statements of Cash Flows​9
​Notes to Condensed Consolidated Financial Statements​10
ITEM 2Management’s Discussion and Analysis of Financial Condition and Results of Operations​28
ITEM 3Quantitative and Qualitative Disclosure About Market Risk​40
ITEM 4Controls and Procedures​40
PART IIOTHER INFORMATION​41
ITEM 1.Legal Proceedings​41
ITEM 1A.Risk Factors​41
ITEM 2Unregistered Sales of Equity Securities and Use of Proceeds, and Issuer Purchases of Equity Securities​92
ITEM 3Defaults Upon Senior Securities​92
ITEM 4Mine Safety Disclosures​92
ITEM 5Other Information​92
ITEM 6.Exhibits​93
​​​​
Exhibit Index​93
Signatures​95
​LOQTORZI®, whether or not appearing in large print or with the trademark symbol, is a registered trademark of Coherus. Trademarks and trade names of other companies appearing in this Quarterly Report on Form 10-Q are, to the knowledge of Coherus, the property of their respective owners.​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.